Immutep’s Growth and Advancements Boost Market Visibility
PremiumCompany AnnouncementsImmutep’s Growth and Advancements Boost Market Visibility
20d ago
Immutep reports Q1 cash receipts from custmers $20,000
Premium
The Fly
Immutep reports Q1 cash receipts from custmers $20,000
21d ago
Immutep announces first-in-human phase I study of IMP761
Premium
The Fly
Immutep announces first-in-human phase I study of IMP761
1M ago
Immutep’s Efti Shows Promise in Cancer Therapy
PremiumCompany AnnouncementsImmutep’s Efti Shows Promise in Cancer Therapy
2M ago
Immutep announces efficacy, safety results from TACTI-003 Phase IIb trial
Premium
The Fly
Immutep announces efficacy, safety results from TACTI-003 Phase IIb trial
2M ago
Immutep: Quarterly Rebalance of S&P/ASX Indices
Premium
Company Announcements
Immutep: Quarterly Rebalance of S&P/ASX Indices
2M ago
Immutep resports quarterly activities for Q4
PremiumThe FlyImmutep resports quarterly activities for Q4
4M ago
Immutep Advances Cancer Trial with FDA Approval
Premium
Company Announcements
Immutep Advances Cancer Trial with FDA Approval
4M ago
Immutep announces meeting with FDA on Phase III design in NSCLC
Premium
The Fly
Immutep announces meeting with FDA on Phase III design in NSCLC
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100